OncoMatch/Clinical Trials/NCT07777822
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
Is NCT07777822 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including zoldonrasib and pembrolizumab for nsclc.
Treatment: zoldonrasib · pembrolizumab · pemetrexed + cisplatin /carboplatin — The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS g12d
Documented RAS G12D mutation status
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Known PD-L1 status
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy for metastatic nsclc
Cannot have received: ras-directed therapy
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate kidney function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Clinical Trials Group, LLC · Plantation, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07777822 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy for metastatic nsclc, ras-directed therapy disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12d is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify